BR112015030229B1 - Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado - Google Patents
Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado Download PDFInfo
- Publication number
- BR112015030229B1 BR112015030229B1 BR112015030229-7A BR112015030229A BR112015030229B1 BR 112015030229 B1 BR112015030229 B1 BR 112015030229B1 BR 112015030229 A BR112015030229 A BR 112015030229A BR 112015030229 B1 BR112015030229 B1 BR 112015030229B1
- Authority
- BR
- Brazil
- Prior art keywords
- virus
- particle
- antigen
- polypeptide
- seq
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/193—Equine encephalomyelitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/85—Fusion polypeptide containing an RNA binding domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361830436P | 2013-06-03 | 2013-06-03 | |
| US61/830,436 | 2013-06-03 | ||
| US201361906583P | 2013-11-20 | 2013-11-20 | |
| US61/906,583 | 2013-11-20 | ||
| PCT/JP2014/065166 WO2014196648A1 (en) | 2013-06-03 | 2014-06-02 | Malaria vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112015030229A2 BR112015030229A2 (pt) | 2017-08-22 |
| BR112015030229A8 BR112015030229A8 (pt) | 2023-04-11 |
| BR112015030229B1 true BR112015030229B1 (pt) | 2023-04-18 |
Family
ID=52005658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015030229-7A BR112015030229B1 (pt) | 2013-06-03 | 2014-06-02 | Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9512190B2 (https=) |
| EP (1) | EP3004348B1 (https=) |
| JP (1) | JP6734651B2 (https=) |
| KR (2) | KR102494564B1 (https=) |
| CN (1) | CN105431535A (https=) |
| AP (1) | AP2015008926A0 (https=) |
| AU (1) | AU2014275772B2 (https=) |
| BR (1) | BR112015030229B1 (https=) |
| CA (1) | CA2913832C (https=) |
| IL (1) | IL242656B (https=) |
| MX (1) | MX386234B (https=) |
| RU (1) | RU2702163C2 (https=) |
| SG (2) | SG10201709917VA (https=) |
| TW (1) | TWI687442B (https=) |
| WO (1) | WO2014196648A1 (https=) |
| ZA (1) | ZA201508642B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102181258B1 (ko) | 2012-02-16 | 2020-11-20 | 브이엘피 테라퓨틱스 엘엘씨 | 바이러스 유사 입자 조성물 |
| TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| US9969986B2 (en) | 2014-08-08 | 2018-05-15 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| KR102532832B1 (ko) | 2014-09-11 | 2023-05-16 | 브이엘피 테라퓨틱스 인코포레이티드 | 플라비바이러스 바이러스 유사 입자 |
| US10166281B2 (en) * | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| US9968665B2 (en) | 2015-09-16 | 2018-05-15 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| WO2018193063A2 (en) | 2017-04-19 | 2018-10-25 | Institute For Research In Biomedicine | Novel malaria vaccines and antibodies binding to plasmodium sporozoites |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| SG11202005792RA (en) | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| MX2020007077A (es) | 2018-01-04 | 2020-10-28 | Iconic Therapeutics Inc | Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados. |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| TWI891771B (zh) | 2020-04-17 | 2025-08-01 | 美商Ｖｌｐ醫療股份有限公司 | 冠狀病毒疫苗 |
| AU2021264216A1 (en) | 2020-04-30 | 2022-11-10 | Vlp Therapeutics, Inc. | Cytokine immunotherapy |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| WO2023092143A1 (en) * | 2021-11-22 | 2023-05-25 | Novavax AB | Methods and compositions for treating and preventing malaria |
| WO2025064770A2 (en) * | 2023-09-20 | 2025-03-27 | La Jolla Institute of Immunology | Alphavirus t cell epitopes, megapools and uses thereof |
| WO2025084276A1 (ja) * | 2023-10-16 | 2025-04-24 | Ｃｙｎ－Ｋバイオ株式会社 | 肥満の処置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2927892A (en) * | 1991-11-16 | 1993-06-15 | Smithkline Beecham Biologicals (Sa) | Hybrid protein between cs from plasmodium and hbsag |
| AU2003295470A1 (en) * | 2002-11-13 | 2004-06-03 | The United States Of America As Represented By The Secretary Of The Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
| EA016648B1 (ru) * | 2004-10-14 | 2012-06-29 | Круселл Холланд Б.В. | Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии |
| GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| US20100120092A1 (en) * | 2006-08-30 | 2010-05-13 | Hepgenics Pty Ltd. | Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
| EP2370455B1 (en) * | 2008-11-26 | 2019-07-03 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Virus like particle compositions and methods of use |
| WO2011022002A1 (en) * | 2009-08-18 | 2011-02-24 | The Rockefeller University | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
| EP2477650B8 (en) * | 2009-09-18 | 2019-10-09 | FRAUNHOFER USA Inc. | Virus like particles comprising target proteins fused to plant viral coat proteins |
| WO2012006180A1 (en) * | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
| WO2012023995A1 (en) * | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
| US9487563B2 (en) * | 2011-01-31 | 2016-11-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles and methods of use |
| KR102181258B1 (ko) * | 2012-02-16 | 2020-11-20 | 브이엘피 테라퓨틱스 엘엘씨 | 바이러스 유사 입자 조성물 |
| US9969986B2 (en) | 2014-08-08 | 2018-05-15 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
-
2014
- 2014-06-02 SG SG10201709917VA patent/SG10201709917VA/en unknown
- 2014-06-02 JP JP2015558676A patent/JP6734651B2/ja active Active
- 2014-06-02 EP EP14807026.1A patent/EP3004348B1/en active Active
- 2014-06-02 AP AP2015008926A patent/AP2015008926A0/xx unknown
- 2014-06-02 CA CA2913832A patent/CA2913832C/en active Active
- 2014-06-02 CN CN201480043750.5A patent/CN105431535A/zh active Pending
- 2014-06-02 MX MX2015016627A patent/MX386234B/es unknown
- 2014-06-02 KR KR1020217029655A patent/KR102494564B1/ko active Active
- 2014-06-02 WO PCT/JP2014/065166 patent/WO2014196648A1/en not_active Ceased
- 2014-06-02 IL IL242656A patent/IL242656B/en unknown
- 2014-06-02 SG SG11201509614SA patent/SG11201509614SA/en unknown
- 2014-06-02 KR KR1020157035411A patent/KR20160016856A/ko not_active Ceased
- 2014-06-02 RU RU2015155821A patent/RU2702163C2/ru active
- 2014-06-02 AU AU2014275772A patent/AU2014275772B2/en not_active Ceased
- 2014-06-02 BR BR112015030229-7A patent/BR112015030229B1/pt not_active IP Right Cessation
- 2014-06-03 TW TW103119188A patent/TWI687442B/zh not_active IP Right Cessation
- 2014-06-03 US US14/294,968 patent/US9512190B2/en active Active
-
2015
- 2015-11-24 ZA ZA2015/08642A patent/ZA201508642B/en unknown
-
2016
- 2016-10-21 US US15/299,859 patent/US20170035871A1/en not_active Abandoned
-
2019
- 2019-03-28 US US16/367,374 patent/US20190351041A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9512190B2 (en) | Malaria vaccine | |
| US9969986B2 (en) | Virus like particle comprising modified envelope protein E3 | |
| Denis et al. | Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization | |
| US10464986B2 (en) | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen | |
| RU2705301C2 (ru) | Композиция вирусоподобных частиц | |
| US10385101B2 (en) | Virus like particle comprising modified envelope protein E3 | |
| JP2024105291A (ja) | Ｂ型肝炎感染症を処置するための方法および組成物 | |
| OA17590A (en) | Malaria Vaccine | |
| RU2811991C2 (ru) | Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей | |
| NZ714285B2 (en) | Malaria vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: VLP THERAPEUTICS, INC. (US) |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/06/2014, OBSERVADAS AS CONDICOES LEGAIS |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2830 DE 01-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |